Inactive Instrument

Kancera AB Stock Nasdaq Stockholm

Equities

Biotechnology & Medical Research

End-of-day quote Nasdaq Stockholm
- SEK - Intraday chart for Kancera AB

Financials

Sales 2024 * - Sales 2025 * 209M 19.84M 27.27M Capitalization 208M 19.76M 27.17M
Net income 2024 * -68M -6.46M -8.88M Net income 2025 * 175M 16.61M 22.84M EV / Sales 2024 * -
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 1 x
P/E ratio 2024 *
-2.86 x
P/E ratio 2025 *
1.18 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 45.56%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer - 22-02-28
Director of Finance/CFO 75 -
Chief Tech/Sci/R&D Officer - 12-12-31
Members of the board TitleAgeSince
Chairman 63 10-05-04
Director/Board Member 66 15-12-31
Founder 82 10-04-27
More insiders
Kancera AB is a Sweden-based company that develops and sells drug candidates in the field of cancer. The Company's activities are divided into two areas, namely Pharmaceutical Development and Industrial Research and Development (R&D). Pharmaceutical Development area runs such projects, as Project PFKFB3, which aims to develop a drug to combat solid tumors; and Project ROR-1, which aims to develop a drug to combat chronic lymphatic leukemia (CLL). Industrial R&D area consists of the identification of new projects of high potential and of R&D work commissioned by clients. The Company's other activities include development of cancer models and stem cell-based techniques. The Company is active through its subsidiary iNovacia, which carries out analytical development, as well as the identification, validation and further optimization of drug candidates. The Company's operations are conducted at the Karolinska Institutet Science Park in Solna, Sweden.
Calendar
More about the company